Market Cap 1.33B
Revenue (ttm) 76.30M
Net Income (ttm) -122.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.81%
Debt to Equity Ratio 0.00
Volume 2,688,800
Avg Vol 588,708
Day's Range N/A - N/A
Shares Out 75.17M
Stochastic %K 21%
Beta 1.51
Analysts Strong Sell
Price Target $24.65

Company Profile

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform in...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 274 8744
Address:
108 Patriot Drive, Suite A, Middletown, United States
KirRoyalTrader
KirRoyalTrader Oct. 27 at 6:32 PM
$ZYME Powerful rebound on the base breakout retest — and look at that massive daily volume bar (and the day’s not even over yet)!
1 · Reply
jimmythetulip
jimmythetulip Oct. 27 at 4:23 PM
$ZYME lots of volume. Something coming?
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 3:00 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ZYME Current Share Price: $17.68 Contracts: $ZYME April 17, 2026 $20 Calls Scale in: $5.13- $6.27 Scale out: $7.98-$10.26 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
notreload_ai
notreload_ai Oct. 24 at 4:54 PM
H.C. Wainwright sets $26 price target for $ZYME after Phase 1 data shows ZW191 cancer drug outperforms FDA-approved competitor with 44% response rate. https://notreload.xyz/hc-wainwright-rates-zymeworks-buy-promising-zw191-cancer-drug-data/
0 · Reply
mostbullish
mostbullish Oct. 24 at 3:57 PM
$ZYME how tf can sentiment be bearish on this. Somebody wants to buy before it 🚀
0 · Reply
mostbullish
mostbullish Oct. 24 at 3:55 PM
$ZYME better get onboard now that the platform has been validated and before GEA data hits
0 · Reply
buylowandwait
buylowandwait Oct. 24 at 3:28 PM
$ZYME 1) Strong cash supporting growth 2) Excellent pipeline with early promising results in a hot ADC sector. 3) Existing royalty from Jazz provide additional cash for advancing pipeline. 4) Big Bio fund is behind this company Holding since single digits.
0 · Reply
JFais
JFais Oct. 24 at 2:23 PM
$ZYME- still not responding to the encouraging FRα data (for some reason, had this marked as a 2026 event) Between this target & GPCR ADC, could see nice accelerating clinical momentum 2026 to 2028 period (continuous data readouts to keep WS interested)
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 11:14 AM
Wells Fargo has adjusted their stance on Zymeworks ( $ZYME ), setting the rating to Equal-Weight with a target price of 14 → 15.
1 · Reply
Mikelonggggggggg
Mikelonggggggggg Oct. 23 at 8:42 PM
1 · Reply
Latest News on ZYME
Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript

Oct 23, 2025, 9:47 PM EDT - 3 days ago

Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript


Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 4:33 PM EDT - 2 months ago

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript


Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:00 PM EDT - 6 months ago

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript


Zymeworks: Poised For Growth With Platform Validation

Apr 28, 2025, 10:48 AM EDT - 6 months ago

Zymeworks: Poised For Growth With Platform Validation


Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 8:43 PM EST - 8 months ago

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript


3 Biotech Stocks With Notable Insider Buying

Jan 22, 2025, 12:29 PM EST - 9 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT JAZZ ONC XBI


Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 10:05 PM EDT - 1 year ago

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript


Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27, 2024, 2:47 PM EDT - 1 year ago

Zymeworks Approaching A Moment Of Truth With Zanidatamab


Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:58 PM EDT - 1 year ago

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript


KirRoyalTrader
KirRoyalTrader Oct. 27 at 6:32 PM
$ZYME Powerful rebound on the base breakout retest — and look at that massive daily volume bar (and the day’s not even over yet)!
1 · Reply
jimmythetulip
jimmythetulip Oct. 27 at 4:23 PM
$ZYME lots of volume. Something coming?
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 3:00 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ZYME Current Share Price: $17.68 Contracts: $ZYME April 17, 2026 $20 Calls Scale in: $5.13- $6.27 Scale out: $7.98-$10.26 Can Easily Capture: 60% ROI Blended DTE: 176 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
notreload_ai
notreload_ai Oct. 24 at 4:54 PM
H.C. Wainwright sets $26 price target for $ZYME after Phase 1 data shows ZW191 cancer drug outperforms FDA-approved competitor with 44% response rate. https://notreload.xyz/hc-wainwright-rates-zymeworks-buy-promising-zw191-cancer-drug-data/
0 · Reply
mostbullish
mostbullish Oct. 24 at 3:57 PM
$ZYME how tf can sentiment be bearish on this. Somebody wants to buy before it 🚀
0 · Reply
mostbullish
mostbullish Oct. 24 at 3:55 PM
$ZYME better get onboard now that the platform has been validated and before GEA data hits
0 · Reply
buylowandwait
buylowandwait Oct. 24 at 3:28 PM
$ZYME 1) Strong cash supporting growth 2) Excellent pipeline with early promising results in a hot ADC sector. 3) Existing royalty from Jazz provide additional cash for advancing pipeline. 4) Big Bio fund is behind this company Holding since single digits.
0 · Reply
JFais
JFais Oct. 24 at 2:23 PM
$ZYME- still not responding to the encouraging FRα data (for some reason, had this marked as a 2026 event) Between this target & GPCR ADC, could see nice accelerating clinical momentum 2026 to 2028 period (continuous data readouts to keep WS interested)
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 11:14 AM
Wells Fargo has adjusted their stance on Zymeworks ( $ZYME ), setting the rating to Equal-Weight with a target price of 14 → 15.
1 · Reply
Mikelonggggggggg
Mikelonggggggggg Oct. 23 at 8:42 PM
1 · Reply
DARKP00L
DARKP00L Oct. 23 at 4:47 PM
$ZYME 12:32 on Oct. 23 2025 Zymeworks Announces Preliminary Results From Phase 1 Study Evaluating ZW191, ADC Targeting Folate Receptor-Alpha, At AACR-NCI-EORTC Conference #tradeideas
0 · Reply
DARKP00L
DARKP00L Oct. 23 at 4:35 PM
$ZYME 12:32 on Oct. 23 2025 Zymeworks Announces Preliminary Results From Phase 1 Study Evaluating ZW191, ADC Targeting Folate Receptor-Alpha, At AACR-NCI-EORTC Conference #tradeideas
0 · Reply
SKL05
SKL05 Oct. 23 at 8:47 AM
$ZYME wow they just dropped this by 15% with just 124 shares traded.
1 · Reply
Boris_Badenov
Boris_Badenov Oct. 22 at 4:17 PM
$ZYME abstract is out
2 · Reply
trading_momentum_x
trading_momentum_x Oct. 22 at 12:06 PM
🧬 $ZYME (Zymeworks Inc) Broke below 17.75 cluster and heading into lower support near 17.20. Strong selling pressure with no bounce attempt yet. Bulls need to reclaim 17.75 to shift bias back up. Weak below that.
0 · Reply
FastProfitAlert
FastProfitAlert Oct. 22 at 6:34 AM
$ZYME extended 1.5% before rejecting leaning bearish short-term 📉⚠️ Watch for breakdown below 9 EMA; next stop could be FVG zone 👀 Potential long setup only on FVG retest with 20 EMA confluence 🔄
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 21 at 12:57 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ZYME Current Share Price: $18.40 Contracts: $ZYME April 17, 2026 $20 Calls Scale in: $5.09- $6.22 Scale out: $7.91-$10.17 Can Easily Capture: 60% ROI Blended DTE: 180 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 18 at 3:59 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ZYME Current Share Price: $18.55 Contracts: $ZYME April 17, 2026 $20 Calls Scale in: $5.54- $6.77 Scale out: $8.61-$11.07 Can Easily Capture: 60% ROI Blended DTE: 182 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
topstockalerts
topstockalerts Oct. 16 at 7:19 PM
JPMorgan indicated that Zymeworks Inc. could see a rise following the release of initial Phase 1 data on its folate receptor α-targeted ADC, ZW191, next week. The brokerage placed the stock on positive catalyst watch ahead of presentations at the AACR-NCI-EORTC International Conference. ZW191 is being evaluated in ovarian, endometrial, and non-small cell lung cancer in a dose-escalation study with around 145 patients. JPMorgan noted that the first data cut may provide insights into early efficacy, safety, and therapeutic window, though it may be too soon to assess response duration. The abstract will be released Wednesday at 1:00 PM, with a poster presentation Thursday at 12:30 PM and a company-hosted webcast at 3:30 PM. JPMorgan highlighted that much of Zymeworks' product portfolio upside has yet to be reflected in its stock price. Reflecting the upcoming catalyst and updated success probability assumptions for ZW191. $JPM $ZYME
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 16 at 5:00 PM
The attachment compares the FY2028 revenue multiples (market cap & enterprise value) of all commercial-stage oncology focused bios with 1st approvals since 1/1/2020 with market caps of $800MM to $2.5B versus commercial-stage non-oncology with 1st approvals since 1/1/2020. The graphs (raw data at the bottom) visually demonstrate oncology continues to trade at lower multiples than non-oncology by roughly 20%. This means, in theory, all commercial-stage oncology focused bios could run 20% higher & would trade at like multiples in non-oncology. This is not investment advice but Centerview Partners once noted oncology focused M&A multiples were historically 10% higher than non-oncology (the report was from FY2019 per the Tesaro transaction). Of particular note, $SNDX continues to be one of the more compelling opportunities if, and these are huge ifs, SNDX revenue forecasts are credible and if SNDX's drugs are worth peer multiples. $ZYME continues to trade at high multiples. $DAWN $IOVA $MESO
1 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 11:49 AM
JP Morgan has adjusted their stance on Zymeworks ( $ZYME ), setting the rating to Overweight with a target price of 20 → 23.
1 · Reply
Doozio
Doozio Oct. 15 at 11:35 PM
🐒🍌🧠 $ZYME ♾️ is in $RYTM in its PRIM
0 · Reply